Advertisement

Related Videos

Boon-Cher Goh, MD, on Cancer Drugs in Singapore: 3As (Availability, Accessibility, and Affordability)

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Welcome and Introduction to Vi3C

Deborah Collyar: What's In It for Patients?

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

Advertisement

Advertisement




Mar
17
Today In Oncology
Benmelstobart Plus Anlotinib in First-Line Treatment for PD-L1–Positive Advanced NSCLC
Optical Genome Mapping Detects Additional Genetic Variants in Nearly 20% of Individuals With Acute Leukemia
New Prostate Cancer Risk Classification With PSMA-PET
FDA Consolidates Systems Into One Cohesive Adverse Event Monitoring Tool
No Recurrence-Free Survival Benefit With Adjuvant Pembrolizumab in Hepatocellular Carcinoma
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo